The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move that boosts visibility for small-cap biotech firms, Elicio Therapeutics (Nasdaq: ELTX) was added to the Russell 2000 and Russell 3000 indexes effective after the U.S. market close on June 26, 2026, according to a company announcement. The inclusion is expected to attract passive fund inflows, potentially supporting the stock which trades at low levels.
Elicio Therapeutics shares closed at $4.00 on June 26, 2026, up from an intraday low of $3.63, per market data. Russell index additions typically lead to higher trading volumes and institutional interest, especially for thinly traded small-cap stocks.
Sign in to access this content
Sign InAt the June 26 close, ELTX traded at $4.00, near its session high of $4.10, reflecting cautious optimism. Investors will watch for upcoming clinical milestones and whether the index inclusion translates into sustained liquidity gains.